Introduced by global pharmaceutical company ‘Full Life’
“Radiopharmaceutical RPT business begins in earnest”
(Seoul = Newsis) SK Biopharm logo. (Photo = Newsis DB) (email protected) *Resale and DB prohibited
(Seoul = Newsis) Reporter Song Yeon-ju = Bio company SK Biopharm is launching a full-scale development project for radiopharmaceuticals (RPT).
SK Biopharmaceuticals announced on the 17th that it has signed a licensing (technology introduction) agreement with Full-Life Technologies, a Hong Kong-based pharmaceutical company, to acquire the global development and commercialization rights for ‘FL-091’, a radiopharmaceutical candidate targeting ‘NTSR1’ (neurotensin receptor).
The introduction of this technology is a decision in line with the strategy of expanding into the field of anticancer treatment through new treatments such as radiopharmaceuticals (RPT) and targeted protein degradation (TPD) beyond the central nervous system, and growing into a big biotech.
The contract is worth $571.5 million (approximately KRW 792.1 billion), including an upfront fee and development and sales milestone payments.
FL-091 is a small molecule radiopharmaceutical designed to deliver actinium-225, a next-generation radioisotope that can kill cancer cells, by selectively binding to NTSR1, a receptor protein that is overexpressed in various types of solid cancers, including colon, prostate, and pancreatic cancer.
SK Biopharmaceuticals also secured certain priority negotiation rights for FullyLife’s radioactive drug conjugate (RDC) programs.
SK Biopharmaceuticals CEO Lee Dong-hoon said, “This licensing agreement is the most concrete achievement since our company declared its entry into the radiopharmaceutical treatment field last year,” and added, “We plan to disclose a more specific business plan for the entire RPT business within this year and accelerate clinical development and commercialization.”
◎ Sympathetic Media Newsis (email protected)
Source: www.newsis.com
